Can the MitraClip Procedure Help Me?

Can the MitraClip Procedure
Help Me?

If your doctor has determined that you are too sick for open-heart surgery, you may be eligible for a less-invasive treatment option that is now available. This procedure is called transcatheter mitral valve repair (TMVR) with MitraClip therapy.

How MitraClip therapy is different

Unlike surgery, the MitraClip procedure does not require opening the chest and temporarily stopping the heart. Instead, doctors access the mitral valve with a thin tube (called a catheter) that is guided through a vein in your leg to reach your heart.

The MitraClip device is a small clip that is attached to your mitral valve. It treats mitral regurgitation by allowing your mitral valve to close more completely, helping to restore normal blood flow through your heart.

MitraClip vs Dime image

What are the possible benefits of the MitraClip procedure?

As of July 2017, over 50,000 patients have been treated with the MitraClip device globally. In clinical studies in the U.S., more than 1,200 patients have undergone the MitraClip procedure, and over 900 of these patients have been followed for 1 year.

Clinical data from patients who underwent the MitraClip procedure demonstrate an immediate reduction of mitral regurgitation and a low hospital length of stay of 2.9 days. You should experience significant improvement in your symptoms of mitral regurgitation and quality of life soon after your procedure.

Calendar icon

Low hospital length of stay

Icon of a person walking

Improved quality of life

Less than 73 percent icon with an arrow pointing down

73% reduction in hospital visits for heart failure

Patients who were studied 1 year after the MitraClip procedure continued to experience improvement in their quality of life and ability to perform day-to-day tasks. They also had fewer visits to the hospital for complications due to heart failure.

Icon of a video camera

Watch Betty's MitraClip journey and learn more about how the procedure works and whether or not MitraClip could be an option for you.

Want to learn more about the MitraClip procedure and if it may be right for you?


The TMVR procedure is not right for everyone. In certain cases, the risks of the procedure may outweigh the benefits. See the important safety information below to review the risks of TMVR with the MitraClip procedure. You should also discuss with your doctor how the risks of the MitraClip procedure compare with other options that may be available to you.

Risks, Warnings, and Precautions

What Are the Possible Risks 1 Year After the Procedure?
The most common serious risks observed within 1 year of the MitraClip procedure in patients enrolled in the PR DMR Cohort include:
  • Death from any cause occurred in 30 out of 127 patients (23.6%)
  • Stroke occurred in 3 out of 127 patients (2.4%). Stroke is a condition where lack of blood flow to the brain causes rapid loss of brain function
  • Ventilation longer than 48 hours occurred in 6 out of 127 patients (4.7%). This means that the use of a ventilator was required more than two days to help a patient breathe
  • Major vascular complications occurred in 9 out of 127 patients (7.1%). Examples include a hematoma (large blood clot under the skin) or damage to the artery and surrounding veins where the catheter was inserted that requires surgical repair
  • Bleeding events occurred in 25 out of 127 patients (19.7%). This refers to a loss of blood related to the procedure that required blood transfusion of 2 or more unit
  • Kidney failure occurred in 5 out of 127 patients (3.9%)
  • Gastrointestinal complications occurred in 3 out of 127 patients (2.4%)
  • Septicemia occurred in 6 out of 127 patients (4.7%). Septicemia is a serious infection of the blood often caused by bacteria
  • MitraClip therapy should only be used in patients with significant, symptomatic, degenerative mitral regurgitation who are too sick for mitral valve surgery.
  • MitraClip therapy is intended to reduce mitral regurgitation. If mitral regurgitation is not reduced enough, you may not get the full treatment benefits of reduced hospitalizations and improvement in heart failure symptoms and quality of life expected from MitraClip therapy.
  • MitraClip therapy should only be used in patients considered to be too sick for surgery. This is determined by the clinical judgment of a heart team, including a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, based on the presence of one or more surgical risk factors.
  • The major clinical benefits of MitraClip therapy are reduction of mitral regurgitation, resulting in reduced hospitalizations and improvement in heart failure symptoms and quality of life. No benefit on how long a patient survives following MitraClip therapy has been demonstrated. How long the MitraClip device will last is unknown at this time.
  • The first MitraClip device was implanted in 2003 and laboratory testing supports durability of the device over a period of 15 years. Regular medical follow-up is essential to evaluate how the MitraClip device is performing. Notify your doctor immediately if you experience the return of any symptoms related to mitral regurgitation.
  • Patients who have undergone MitraClip therapy should receive prophylactic antibiotic therapy before any medical or dental procedure to minimize the possibility of infection.
  • The safety and effectiveness of MitraClip therapy have not been established in patients who have functional (also called secondary) mitral regurgitation.
  • The safety and effectiveness of MitraClip therapy have not been established in patients who have specific mitral valve anatomy that may interfere with proper placement and positioning of the MitraClip device:
    • A mitral valve opening that is too small
    • Calcified mitral valve leaflets
    • A cleft of the mitral valve leaflet
    • A leaflet flail width or leaflet flail gap that is too large
  • MitraClip therapy has not been tested in pregnant women or children or infants, and the device may not work for these patients.